Evidence map›Paper›PMID 41503190›Full record

ArticleKidney medicine2026

Cyclophosphamide Plus Rituximab Versus Cyclophosphamide in Antineutrophil Cytoplasmic Antibody-associated Vasculitis With Kidney Involvement: A Retrospective Cohort Study in China.

Jiahui Wang, Xin Lei, Junni Wang, Wanyun Nie, Xiaohan Huang, Huanhuan Zhu, Liangliang Chen, Nan Shi, Yaomin Wang, Lan Lan and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jiahui WangKidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Xin LeiKidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Junni WangKidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Wanyun NieKidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Xiaohan HuangKidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Huanhuan ZhuKidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Liangliang ChenKidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Nan ShiKidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Yaomin WangKidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Lan LanKidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Pingping RenKidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Jianghua ChenKidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Fei HanKidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale & Objective: Intravenous cyclophosphamide (CTX) or rituximab (RTX) combined with glucocorticoids are first-line therapies for antineutrophil cytoplasmic antibody-associated vasculitis (AAV). We aimed to compare the efficacy of CTX plus RTX and CTX alone, in combination with glucocorticoids, for AAV patients with kidney injury. Study Design: Retrospective cohort study. Setting & Participants: 76 newly diagnosed AAV patients with kidney involvement, divided into glucocorticoids plus CTX group (control group, n = 36) and glucocorticoids plus CTX and RTX group (combination group, n = 40). Exposure: CTX plus RTX or CTX alone, in combination with glucocorticoids. Outcomes: Kidney failure, remission, death, combined events endpoint of kidney failure and/or death, relapse, and adverse events. Analytical Approach: Unpaired Results: The median follow-up period was 29.7 (20.4-37.4) months. The remission rate was significantly higher in the combination group than in the control group at 6 months (85.0% vs 52.8%, Limitations: Primarily Chinese, retrospective data. Conclusions: The combination of glucocorticoids, CTX, and RTX is better in achieving early disease remission and reducing the dose of glucocorticoids for AAV patients.

Indexed as

ANCA-associated vasculitiscyclophosphamidekidneyremissionrituximab

Identifiers

PMID41503190
PMCPMC12771095

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.